Phathom Pharmaceuticals Files DEFA14A Proxy Materials

TL;DR

Phathom Pharma dropped proxy docs 4/7/26. Shareholders vote soon.

AI Summary

Phathom Pharmaceuticals, Inc. filed a DEFA14A form on April 7, 2026, related to additional definitive proxy soliciting materials. The filing includes various documents such as an iXBRL DEFA14A, graphic files, and XBRL data. The company's mailing and business address is 100 Campus Drive, Suite 102, Florham Park, NJ 07932.

Why It Matters

This filing indicates that Phathom Pharmaceuticals is engaging in proxy solicitations, which are crucial for shareholder voting on important company matters.

Risk Assessment

Risk Level: low — This filing is a standard proxy solicitation document and does not inherently indicate significant financial risk.

Key Numbers

• 0001783183 — CIK Number (Identifies Phathom Pharmaceuticals, Inc. in SEC filings.)
• 2026-04-07 — Filing Date (Date Phathom Pharmaceuticals, Inc. filed the DEFA14A.)

Key Players & Entities

• Phathom Pharmaceuticals, Inc. (company) — Filer of the DEFA14A
• 0001783183 (company) — CIK number for Phathom Pharmaceuticals, Inc.
• 2026-04-07 (date) — Filing date of the DEFA14A
• 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 (company) — Mailing and Business Address for Phathom Pharmaceuticals, Inc.

FAQ

Filing Documents

• phat-20260406.htm (DEFA14A) — 20KB
• img93183329_0.jpg (GRAPHIC) — 227KB
• img93183329_1.jpg (GRAPHIC) — 150KB
• 0001193125-26-144578.txt ( ) — 1043KB
• phat-20260406.xsd (EX-101.SCH) — 7KB
• phat-20260406_htm.xml (XML) — 1KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 Phathom Pharmaceuticals, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Your Vote Counts!PHATHOM PHARMACEUTICALS, INC.2026 Annual Meeting Vote by May 18, 2026 11:59 PM ET PHATHOM PHARMACEUTICALS, INC.100 CAMPUS DRIVE, SUITE 102FLORHAM PARK, NJ 07932V89187-P46902You invested in PHATHOM PHARMACEUTICALS, INC. and it's time to vote!You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 19, 2026.Get informed before you vote View the Annual Report and Notice and Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 5, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control #Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting*May 19, 2026 9:00 AM EDT Virtually at:www.virtualshareholdermeeting.com/PHAT2026*Please check the meeting materials for any special requirements for meeting attendance. Vote at www.ProxyVote.comTHIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items 1. To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders. Nominees: Steven Basta For Theodore R. Schroeder For Mark Stenhouse For 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. For 3. To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay"). NOTE: Such other business as may properly come before the meeting or any adjournment thereof. Pref er to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".